According to Vision Research Reports, the global hypopigmentation disorder treatment market size is expected to hit around US$ 2.15 billion by 2027 and is projected to expand at a CAGR of 5.8% from 2020 to 2027. Rise in prevalence of hypopigmentation disorders across the world is anticipated to drive the global hypopigmentation disorder treatment market during the forecast period.
Asia Pacific and North America are projected to dominate the global hypopigmentation disorder treatment market during the forecast period. The market in these regions is primarily driven by increase in government initiatives and awareness about vitiligo and other hypopigmentation disorders. The market in Asia Pacific is anticipated to expand at a high CAGR from 2020to 2027. The hypopigmentation disorder treatment market in North America is expected to expand at a moderate CAGR during the forecast period. The hypopigmentation disorder treatment market in Latin America is likely to grow at a moderate pace from 2020 to 2027.
Increase in Usage of Topical Drugs as Treatment Option to Boost Market
In terms of treatment, the topical drugs segment is projected to account for dominant share of the global hypopigmentation disorder treatment market during the forecast period. The segment is anticipated to expand at a high CAGR from 2020 to 2027. Dominance of the segment is attributed to increase in patient preference for topical drugs as the first line of treatment due to lower cost and higher efficacy. The chemical peels segment held major share of the market in 2019, followed by the topical drugs segment, due to increase in acceptance and popularity of chemical peels by dermatologists as well as patients. The laser therapy and microdermabrasion segments accounted for around 10.0% share of the global hypopigmentation disorder treatment market in terms of revenue in 2019.
Vitiligo Segment Dominated the Market
The report offers detailed segmentation of the global hypopigmentation disorder treatment market based on treatment, disease indication, and end-user. In terms of disease indication, the market has been classified into vitiligo, albinism, and others. The vitiligo segment is projected to account for leading share of the global market during the forecast period. Higher share of the segment is attributed to rise in the number of patients undergoing treatment for vitiligo. According to the Global Vitiligo Foundation, currently 70 million people across the world and about 2.7 million people in the U.S. have vitiligo.
Aesthetic Clinics & Dermatology Centers Segment to Expand at High CAGR
Based on end-user, the aesthetic clinics & dermatology centers segment accounted for a leading share of the global hypopigmentation disorder treatment market in 2019. The segment is projected to gain market share from 2020 to 2027. The segment is anticipated to expand at a high CAGR during the forecast period due to the well-developed aesthetic clinic & dermatology center infrastructure, increase in adoption of new devices and techniques by aesthetic clinics & dermatology centers, and quality of expertise available in clinics. Hospitals was a prominent segment of the global market in 2019, followed by the aesthetic clinics & dermatology centers segment. This is due to increase in the number of multi-specialty hospitals in developing countries.
Asia Pacific to be Highly Lucrative Market for Hypopigmentation Disorder Treatment
The hypopigmentation disorder treatment market in Asia Pacific is driven by rise in medical tourism in countries such as India and China, increase in geriatric population, surge in health care spending, and government initiatives. High population, unmet medical needs, and rise in patient awareness are also anticipated to propel the market in the region. Economic growth in emerging economies such as India and China is enhancing the buying capabilities of consumers due to an increase in disposable income. This is likely to boost the market in the country in the near future.
Trend of Strategic Alliance with Local Companies to Strengthen Distribution Network and Expand Geographic Presence
The global hypopigmentation disorder treatment market is fragmented, owing to the presence of several small and large companies. However, the market is dominated by a few major players with strong global presence. The report provides profiles of leading players operating in the global hypopigmentation disorder treatment market. Key players in the market include Allergan, SkinCeuticals, Pierre Fabre, Episciences, Inc., RXi Pharmaceuticals Corporation, Obagi Cosmeceuticals LLC (Obagi Medical), and Alvogen.
The report analyzes and forecasts the hypopigmentation disorder treatment market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2020 to 2027. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of hypopigmentation disorder treatment, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major hypopigmentation disorder treatment companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of hypopigmentation disorder treatment upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of hypopigmentation disorder treatment and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global hypopigmentation disorder treatment market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the hypopigmentation disorder treatment market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of hypopigmentation disorder treatment market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Companies Mentioned in Report
The report also profiles major players in the global hypopigmentation disorder treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players profiled in the market report include Allergan, SkinCeuticals, Pierre Fabre, Episciences, Inc., RXi Pharmaceuticals Corporation, Obagi Cosmeceuticals LLC (Obagi Medical), and Alvogen.
Report Segmentation:
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Market Overview
4.2. Global Hypopigmentation Disorders Treatment Market Analysis
4.3. Global Hypopigmentation Disorders Treatment Market Overview
4.4. Porter’s Five Forces Analysis
4.5. Pipeline Analysis
4.6. Key Partnership & Acquisitions
4.7. Disease Prevalence and Incidence: Global Overview
4.8. Regulatory Scenario
5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Key Trends
6. Global Hypopigmentation Disorders Treatment Market Analysis, by Treatment
6.1. Introduction
6.2. Global Hypopigmentation Disorders Treatment Market Value Share Analysis, by Treatment
6.3. Global Hypopigmentation Disorders Treatment Market Forecast, by Treatment
6.4. Global Hypopigmentation Disorders Treatment Market Analysis, by Treatment
6.4.1. Topical Drugs
6.4.2. Laser Therapy
6.4.3. Chemical Peels
6.4.4. Microdermabrasion
6.4.5. Others (phototherapy, etc.)
6.5. Global Hypopigmentation Disorders Treatment Market Attractiveness Analysis, by Treatment
7. Global Hypopigmentation Disorders Treatment Market Analysis, by Disease Indication
7.1. Introduction
7.2. Global Hypopigmentation Disorders Treatment Market Value Share Analysis, by Disease Indication
7.3. Global Hypopigmentation Disorders Treatment Market Forecast, by Disease Indication
7.4. Global Hypopigmentation Disorders Treatment Market Analysis, by Disease Indication
7.4.1. Vitiligo
7.4.2. Albinism
7.4.3. Others
7.5. Global Hypopigmentation Disorders Treatment Market Attractiveness Analysis
8. Global Hypopigmentation Disorders Treatment Market Analysis, by End-user
8.1. Introduction
8.2. Global Hypopigmentation Disorders Treatment Market Value Share Analysis, by End-user
8.3. Global Hypopigmentation Disorders Treatment Market Forecast, by End-user
8.4. Global Hypopigmentation Disorders Treatment Market Analysis, by End-user
8.4.1. Hospitals
8.4.2. Aesthetic Clinics & Dermatology Centers
8.4.3. Others
8.5. Global Hypopigmentation Disorders Treatment Market Attractiveness Analysis, by End-user
9. Global Hypopigmentation Disorders Treatment Market Analysis, by Region
9.1. Global Market Scenario
9.2. Global Hypopigmentation Disorders Treatment Market Value Share Analysis, by Region
9.3. Global Hypopigmentation Disorders Treatment Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Global Hypopigmentation Disorders Treatment Market Attractiveness Analysis, by Region
10. North America Hypopigmentation Disorders Treatment Market Analysis
10.1. North America Hypopigmentation Disorders Treatment Market Analysis
10.2. North America Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Country
10.3. North America Hypopigmentation Disorders Treatment Market Forecast, by Country
10.3.1. U.S.
10.3.2. Canada
10.4. North America Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Treatment
10.5. North America Hypopigmentation Disorders Treatment Market Forecast, by Treatment
10.5.1. Topical Drugs
10.5.2. Laser Therapy
10.5.3. Chemical Peels
10.5.4. Microdermabrasion
10.5.5. Others (phototherapy, etc.)
10.6. North America Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Disease Indication
10.7. North America Hypopigmentation Disorders Treatment Market Forecast, by Disease Indication
10.7.1. Vitiligo
10.7.2. Albinism
10.7.3. Others
10.8. North America Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by End-user
10.8.1. Hospitals
10.8.2. Aesthetic Clinics & Dermatology Centers
10.8.3. Others
11. Europe Hypopigmentation Disorders Treatment Market Analysis
11.1. Europe Hypopigmentation Disorders Treatment Market Analysis
11.2. Europe Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.3. Europe Hypopigmentation Disorders Treatment Market Forecast, by Country/Sub-region
11.3.1. Germany
11.3.2. France
11.3.3. U.K.
11.3.4. Italy
11.3.5. Spain
11.3.6. Rest of Europe
11.4. Europe Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Treatment
11.5. Europe Hypopigmentation Disorders Treatment Market Forecast, by Treatment
11.5.1. Topical Drugs
11.5.2. Laser Therapy
11.5.3. Chemical Peels
11.5.4. Microdermabrasion
11.5.5. Others (phototherapy, etc.)
11.6. Europe Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Disease Indication
11.7. Europe Hypopigmentation Disorders Treatment Market Forecast, by Disease Indication
11.7.1. Vitiligo
11.7.2. Albinism
11.7.3. Others
11.8. Europe Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by End-user
11.8.1. Hospitals
11.8.2. Aesthetic Clinics & Dermatology Centers
11.8.3. Others
12. Asia Pacific Hypopigmentation Disorders Treatment Market Analysis
12.1. Asia Pacific Hypopigmentation Disorders Treatment Market Analysis
12.2. Asia Pacific Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3. Asia Pacific Hypopigmentation Disorders Treatment Market Forecast, by Country/Sub-region
12.3.1. China
12.3.2. Japan
12.3.3. India
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Asia Pacific Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Treatment
12.5. Asia Pacific Hypopigmentation Disorders Treatment Market Forecast, by Treatment
12.5.1. Topical Drugs
12.5.2. Laser Therapy
12.5.3. Chemical Peels
12.5.4. Microdermabrasion
12.5.5. Others (phototherapy, etc.)
12.6. Asia Pacific Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Disease Indication
12.7. Asia Pacific Hypopigmentation Disorders Treatment Market Forecast, by Disease Indication
12.7.1. Vitiligo
12.7.2. Albinism
12.7.3. Others
12.8. Asia Pacific Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by End-user
12.8.1. Hospitals
12.8.2. Aesthetic Clinics & Dermatology Centers
12.8.3. Others
13. Latin America Hypopigmentation Disorders Treatment Market Analysis
13.1. Latin America Hypopigmentation Disorders Treatment Market Analysis
13.2. Latin America Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3. Latin America Hypopigmentation Disorders Treatment Market Forecast, by Country/Sub-region
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Latin America Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Treatment
13.5. Latin America Hypopigmentation Disorders Treatment Market Forecast, by Treatment
13.5.1. Topical Drugs
13.5.2. Laser Therapy
13.5.3. Chemical Peels
13.5.4. Microdermabrasion
13.5.5. Others (phototherapy, etc.)
13.6. Latin America Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Disease Indication
13.7. Latin America Hypopigmentation Disorders Treatment Market Forecast, by Disease Indication
13.7.1. Vitiligo
13.7.2. Albinism
13.7.3. Others
13.8. Latin America Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by End-user
13.8.1. Hospitals
13.8.2. Aesthetic Clinics & Dermatology Centers
13.8.3. Others
14. Middle East & Africa Hypopigmentation Disorders Treatment Market Analysis
14.1. Middle East & Africa Hypopigmentation Disorders Treatment Market Analysis
14.2. Middle East & Africa Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.3. Middle East & Africa Hypopigmentation Disorders Treatment Market Forecast, by Country/Sub-region
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of MEA
14.4. Middle East & Africa Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Treatment
14.5. Middle East & Africa Hypopigmentation Disorders Treatment Market Forecast, by Treatment
14.5.1. Topical Drugs
14.5.2. Laser Therapy
14.5.3. Chemical Peels
14.5.4. Microdermabrasion
14.5.5. Others (phototherapy, etc.)
14.6. Middle East & Africa Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Disease Indication
14.7. Middle East & Africa Hypopigmentation Disorders Treatment Market Forecast, by Disease Indication
14.7.1. Vitiligo
14.7.2. Albinism
14.7.3. Others
14.8. Middle East & Africa Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by End-user
14.8.1. Hospitals
14.8.2. Aesthetic Clinics & Dermatology Centers
14.8.3. Others
15. Competition Landscape
15.1. Hypopigmentation Disorders Treatment Market Share Analysis, by Company
15.2. Competition Matrix
15.3. Company Profile
15.3.1. Allergan
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. SkinCeuticals
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Pierre Fabre
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Episciences, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Rxi Pharmaceutical Corporation
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Obagi Cosmeceuticals LLC (Obagi Medical)
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Alvogen
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers